Fausto Berti
Zurich, ZH 8050, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 09, 2025
Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 07, 2025
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis.
Journal: Expert opinion on biological therapy
Published: July 23, 2025
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration.
Journal: Expert opinion on biological therapy
Published: June 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adults.
Journal: Expert opinion on investigational drugs
Published: May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adults.
Journal: Expert opinion on investigational drugs
Published: May 13, 2025
The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
Journal: Therapeutic advances in chronic disease
Published: August 07, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Journal: Expert opinion on biological therapy
Published: July 12, 2023
Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02.
Journal: Immunotherapy advances
Published: July 12, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Journal: Expert opinion on investigational drugs
Published: May 22, 2023
Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 10, 2023
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe.
Journal: Expert opinion on biological therapy
Published: October 07, 2022
Last Updated: 09/26/2026